Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites

Engelhardt, Sabine; Meineke, Ingolf; Brockmöller, Jürgen

doi:10.1016/j.jchromb.2005.11.013

Cited by 17 publications

(15 citation statements)

References 7 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, to clarify the peculiarities of sterilization the model batch МС111207 Тоrasemide, solution for injection, 5 mg/ml, in ampoules was sterilized at 121°С for 15 min (the pharmacopeial mode of thermal sterilization), and the changes of the main quality indicators (the quantitative content of Тоrasemide, impurities -decomposition products of Тоrasemide) were observed [2,3,4].…”

Section: Methodsmentioning

confidence: 99%

“…In comparative studies with Furosemide in 234 patients Тоrаsеmіde lowered the risk of hospitalizations by 52% related to CHF exacerbation. Moreover, when examining 2303 patients with CHF who received Тоrаsеmіde or Furosemide randomized in the ratio of 1:1 the reliable decrease of cardiovascular (53%, р<0.013) and general (41%, р=0.035) mortality was shown [1,2]. The aim is to substantiate introduction of the innovative technological process for industrial production of parenteral dosage forms by the example of Тоrаsеmіde, solution for injection.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The substantiation for introduction of the innovative technological process for industrial production of parenteral dosage forms by the example of torasemіde, solution for injection

Goy

2016

Vìsn. farm.

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

The substantiation for introduction of the innovative technological process for industrial production of parenteral dosage forms by the example of torasemіde, solution for injection

Goy

2016

Vìsn. farm.

View full text Add to dashboard Cite

“…21,49 The limit of quantification was 10 ng/ml for all analytes from plasma samples and 1 ng/ml for all analytes from urine samples. Pharmacokinetic analysis was performed with the nonparametric analysis module of the WinNonlin software, version 2.1.…”

Section: Drug Concentration and Pharmacokinetic Analysismentioning

confidence: 99%

Genetic variation at the CYP2C locus and its association with torsemide biotransformation

et al. 2006

View full text Add to dashboard Cite

In 97 unselected volunteers and two additional homozygous carriers of CYP2C9*3, we investigated the oral clearance of torsemide in relation to 37 polymorphisms at the CYP2C gene locus. Torsemide total oral clearance was linearly associated with the number of CYP2C9*3 alleles (geometric mean: 59, 40 and 20 ml/min in carriers of no, one and two alleles) and so were the methyl-and ring-hydroxylation but not the carboxylation clearance. Haplotypes including the CYP2C9*3 allele were similarly associated with the clearances but no other variant and no haplotype not including the CYP2C9*3 variant. The extended haplotype length (EHL) of the CYP2C9 haplotypes was positively associated with higher activity of the gene product. Torsemide total oral clearance was predictable with r 2 ¼ 82.1% using plasma concentrations at 0.5, 1, 2 and 24 h. In conclusion, torsemide's biotransformation strongly depended on the CYP2C9*3 variant but no other. Higher clearance CYP2C9 haplotypes appear to be evolutionarily selected.

show abstract

“…TOR was determined by pharmacopoeial and non-pharmacopoeial methods where it is assayed in the British pharmacopoeia via non-aqueous titration [3], while assayed in the USP pharmacopoeia by HPLC method [4]. The non-pharmacopoeial methods used for determination of TOR include HPLC [5][6][7][8][9], LC/MS [10][11][12][13], GC/MS [14,15], spectrophotometry [16][17][18][19][20] and TLC-densitometry [21]. Stability-indicating HPTLC [22], HPLC [23] and ion selective electrode [24] methods have been recently reported for analysis of TOR but no spectrophotometric studies were performed.…”

Section: Introductionmentioning

confidence: 99%

Development and validation of stability-indicating methods for determination of torsemide

Zaazaa¹,

Abbas²,

Essam³

et al. 2016

Bull. Chem. Soc. Eth.

View full text Add to dashboard Cite

Four sensitive and precise methods for determination of torsemide in presence of its degradation product and in pharmaceutical formulation were developed and validated. Method A is the second derivative spectrophotometry at 262.4 nm with mean percentage recoveries 100.06±0.75. Method B is first derivative of the ratio spectra spectrophotometry, at 232.4, 244.6 nm and at the total peak amplitude from the maximum at 232.4 nm to the minimum at 244.6 nm (1 DD232.4+244.6nm). Method C is a TLC-densitometric one, for torsemide separation using acetone : chloroform : ethyl acetate (4:4:2 v/v) as a developing system. Method D is HPLC one, it provides complete separation of torsemide from its degradation product on C8 column with UV detection at 287 nm and recovery 99.98±0.76. The proposed methods have been successfully applied to the analysis of torsemide in pharmaceutical formulations without interference from other additives and the results were statistically compared with the official method.

show abstract

Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites

Cited by 17 publications

References 7 publications

The substantiation for introduction of the innovative technological process for industrial production of parenteral dosage forms by the example of torasemіde, solution for injection

The substantiation for introduction of the innovative technological process for industrial production of parenteral dosage forms by the example of torasemіde, solution for injection

Genetic variation at the CYP2C locus and its association with torsemide biotransformation

Development and validation of stability-indicating methods for determination of torsemide

Contact Info

Product

Resources

About